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Abstract. Dihydroartemisinin–piperaquine (DP) could become a leading fixed combination malaria treatment
worldwide. Although there is accumulating evidence of efficacy and safety from clinical trials, data on cardiotoxicity are
limited. In two randomized controlled trials in Thailand, 56 patients had ECGs performed before treatment, 4 hours
after the first dose, and 4 hours after the last dose. The mean (95% CI) changes in QTc interval (Bazett’s correction)
were 2 (−6 to 9) ms and 14 (7 to 21) ms, respectively. These small changes on the third day of treatment are similar to
those observed elsewhere in the convalescent phase following antimalarial treatment with drugs known to have no
cardiac effects and are therefore likely to result from recovery from acute malaria and not the treatment given. At
therapeutic doses, DP does not have clinically significant effects on the electrocardiogram.
INTRODUCTION
Dihydroartemisinin–piperaquine (DP) is a fixed combina-
tion antimalarial treatment developed in China. The excellent
efficacy of this combination has been demonstrated in several
large randomized controlled trials. DP has been very well
tolerated.
1–4 Artemisinin derivatives are generally considered
to be safe in terms of cardiotoxic potential, and although QTc
prolongation (Bazett’s correction) has been reported, particu-
larly in toxicological evaluations in dogs with central nervous
system abnormalities,
5,6 clinically significant changes have not
been observed in the treatment of malaria.
7–9 Piperaquine is
structurally similar to chloroquine, which has lethal cardio-
vascular toxicity in overdose and significant electrophys-
iological effects on the heart.
10 Cardiac electrophysiological
studies show that chloroquine blocks the inward sodium cur-
rent, INa (the class 1 effect), the L-type calcium current (ICa-
L), and two potassium currents including the rapid delayed
rectifier outward currents (IKr; the hERG channel) associated
with QT prolongation. There are no corresponding electro-
physiological data for piperaquine. In a study of 62 adults and
children, in Cambodia, electrocardiographic (ECG) findings
after DP treatment showed a significant lengthening of the
mean QTc by 11 ms (95% CI 4–18).
11
Various guidelines exist for the assessment of QT prolon-
gation by noncardiovascular drugs. The U.S. Food and Drug
Administration (FDA) sets a conservative threshold of con-
cern for any drug that causes a mean increase in QTc of 5 ms
and a high level of concern for an increase of 20 ms.
12 The
European Society of Cardiology sets no absolute levels and,
like the FDA, advocates other approaches to assessing the
seriousness of QTc prolongation, such as categorizing the
number of cases of QTc > 500 ms or absolute increases > 60
ms.
12,13
Evaluation of QT interval changes is problematic in ma-
laria because of systematic differences between the acute fe-
brile admission before antimalarial drugs are given and early
convalescence, when the peak antimalarial drug concentra-
tions occur and the repeat ECG measurements are made.
14
At presentation, patients are usually anxious, fasting, and fe-
brile with increased autonomic tone, and a raised heart rate.
This contrasts with the relaxed, fed, supine afebrile state 3
days later, when most antimalarial treatments finish and an-
timalarial drug concentrations are at their highest. It has been
argued that this systematic reduction in sympathetic activity
with recovery leads to a consistent increase in the QT interval,
which has been mistakenly ascribed to antimalarial drug ef-
fects.
14 Studies over a short period of time or in healthy vol-
unteers are preferable. Although Bazett’s formula (QTc 
QT/RR
0.5) is most commonly used to rate-correct the QT
interval, it is inaccurate at high and low heart rates.
10,12,15
Fridericia’s cube-root correction (QTc  QT/RR
0.3) is often
preferred.
12 In the Karen population, we found the optimal
rate correction was QTc  QT/RR
0.4 (Karen formula).
10
This study was part of two randomized trials of DP in the
treatment of uncomplicated malaria on the northwestern bor-
der of Thailand during 2002 and 2003, which have been re-
ported elsewhere.
3,4 Ethical approval for both studies was
obtained from the Faculty of Tropical Medicine, Mahidol
University, Bangkok, and the Oxford Tropical Research Eth-
ics Committee. Patients were Karen or Burmese adults and
children with symptomatic slide-proven uncomplicated falci-
parum malaria. They were given one of two dosing regimes of
DP (Artekin, Holleykin Pharmaceutical Co. Ltd, Guangzhou,
China), total dose 7 mg/kg body weight of dihydroartemisinin
and 55 mg/kg piperaquine, split into four doses at 0 hours, 8
hours, 24 hours, and 48 hours or into three doses at 0, 24, and
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TABLE 1
Correlation between RR interval and QTc interval for the different
methods of QT interval correction
Time
of ECG
Bazett’s Karen Fridericia’s
Pearson
correlation
coefficient P value
Pearson
correlation
coefficient P value
Pearson
correlation
coefficient P value
0 hours −0.347 0.009 −0.097 0.467 0.095 0.484
4 hours −0.340 0.010 0.068 0.621 −0.111 0.414
52 hours −0.050 0.716 0.228 0.091 0.397 0.002
Each method involves QT correction for heart rate by dividing the QT interval by a power
of the RR interval; for Bazett’s, this is 0.5; for the Karen it is 0.4; and for Fridericia’s, it is
0.33.
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44748 hours. ECG monitoring was possible at only one site. All
patients randomized to receive DP had a standard 12-lead
ECG recorded (Autocardiner FCP-2155; Fukuda Denshi Co.,
Ltd., Tokyo, Japan), tracing at 25 mm/s paper speed, at base-
line (0 hours). Repeat ECGs were recorded at 4 hours and 52
hours (4 hours after the first and last doses of DP). The QT
and RR intervals were read manually in lead II, taking the
mean of at least three readings, following FDA guidelines.
12
A second reader independently read all ECGs with a pro-
longed QTc, all ECGs with a QTc prolongation > 50 ms, and
an additional set of ECGs chosen at random, such that a total
of 20% of ECGs were checked. A third reader adjudicated on
any disagreement between the first two readers.
The QT interval was corrected for heart rate using Bazett’s
formula, Fridericia’s formula, and the Karen formula. The
JTc interval was calculated: (QT interval − QRS interval)/
RR
0.4, to separate effects on depolarization from prolonga-
tion in repolarization. Paired t-tests were used to compare the
mean PR, QRS, JTc, and QTc intervals between 0 and 4 hours
and between 0 and 52 hours. The 95% CI for the changes in
QTc were derived from the standard error of the difference of
the two means. The Pearson correlation coefficient was used
to test for an association between the RR interval and QTc,
for each method of rate correction, to determine the correc-
tion least dependent on heart rate. Using this method, the
proportions of ECGs with a prolonged QTc interval (QTc >
450 ms), with an increase > 60 ms, or with an increase > 25%
are presented.
12
Data are presented on 56 patients (44 males and 12 fe-
males) with a median age (range) of 18 (6–60) years. One
patient was excluded because the QT intervals could not be
interpreted due to a poor trace. The median (range) heart
rate at baseline was 95.5 (67–134) bpm, compared with 86
(60–120) bpm, 4 hours after the first dose (P < 0.001), and 69.5
(42–104) bpm, 52 hours after the first dose (P < 0.001). There
was slight prolongation of the mean (SD) PR interval from
132 (14) ms at the baseline to 135 (15) ms (P  0.040) at 4
hours, and 141 (16) ms (P < 0.001) at 52 hours. There was no
PR prolongation > 200 ms. The mean (SD) QRS interval was
unchanged, measuring 83 (12) ms at 4 hours (P  0.226) and
83 (12) ms at 52 hours (P  0.281), compared with 82 (11) ms
at baseline.
The best correction for the QTc was the Karen formula,
which resulted in the weakest correlation between the RR
interval and the QTc (Table 1). There was no significant
change in the mean QTc at 4 hours (Bazett’s QTc [95% CI] 
+2 [−6t o9 ]m s ,P  0.663; Karen formula QTc  +1 [−5t o
9] ms, P  0.622; Fridericia’s QTc  +1 [−5t o9 ]m s ,P 
0.629) and a small increase at 52 hours (Bazett’s QTc [95%
CI]  +14 [7–14] ms, P < 0.001; Karen formula QTc  +24
[16–31] ms, P < 0.001; Fridericia’s QTc  +29 [22–38] ms,
P < 0.001), from baseline (mean QTc Bazett’s  407 ms;
Karen formula  390 ms; Fridericia’s  380 ms). There were
similar changes observed in the mean JTc [95% CI], at 4
hours (0 [−8t o8 ]m s ,P  0.939) and at 52 hours (30 [22–39]
ms, P < 0.001) from baseline (294 ms).
The numbers of patients with QTc lengthening (defined as
> 30 ms and > 60 ms, as specified by the FDA) are shown in
Table 2. Table 3 shows the number of prolonged QTc read-
ings at baseline, 4 hours, and 52 hours. The longest QTc ob-
served was 520 ms at baseline, but this did not increase, mea-
suring 520 ms at 4 hours and 481 ms at 52 hours. The greatest
increase was 107 ms from 387 ms at baseline to 383 ms at 4
hours and 494 ms at 52 hours, in a 19-year-old male, the only
patient to have a QTc prolongation > 25%. No patient, with
a normal baseline QTc, had abnormal readings at both 4 and
52 hours. A total of 684 patients were treated with DP and
followed. Within this group there was one sudden death
within 24 hours of starting treatment; however, this was as-
cribed to severe malaria. No arrhythmias or abnormal ECG
findings were documented in this group.
The electrophysiology findings presented here suggest that
DP does not cause clinically relevant cardiotoxicity. Although
the mean prolongation in the QTc of 14 ms (Bazett’s) ob-
TABLE 2
Number of readings with QTc increases at 4 hours and 52 hours, using the three different methods of QT interval correction
QTC prolongation
from baseline (ms)*
Bazett’s Karen Fridericia’s
4 hours 52 hours 4 hours 52 hours 4 hours 52 hours
< 30 49 (87.5) 42 (75.0) 50 (89.2) 34 (60.7) 49 (87.5) 28 (50.0)
30–60 5 (8.9) 11 (19.6) 5 (8.9) 16 (28.6) 6 (10.7) 20 (35.7)
> 60 2 (3.6) 3 (5.4) 1 (1.8) 6 (10.7) 1 (1.8) 8 (14.3)
Percentages shown in parentheses. Bazett’s, Karen, and Fridericia’s are different forms of QT correction for heart rate, calculated by dividing the QT interval by a power of RR interval; for
Bazett’s, this is 0.5; for the Karen it is 0.4; and for Fridericia’s, it is 0.33.
* Cutoffs used are taken from FDA guidelines.
TABLE 3
Proportion of prolonged QTc readings at baseline, 4 hours, and 52 hours, using the three different methods of QT interval correction
QTc*
Bazett’s( n) Karen (n) Fridericia’s( n)
Baseline 4 hours 52 hours Baseline 4 hours 52 hours 0 hours 4 hours 52 hours
< 450 54 (96.4) 51 (91.1) 50 (89.3) 55 (98.2) 54 (96.4) 53 (94.6) 55 (98.2) 55 (98.2) 53 (94.6)
450–479 1 (1.8) 3 (5.4) 4 (7.1) 0 (0) 1 (1.8) 1 (1.8) 0 (0) 0 (0) 2 (3.6)
480–500 0 (0) 1 (1.8) 2 (3.6) 0 (0) 0 (0) 2 (3.6) 1 (1.8) 1 (1.8) 1 (1.8)
> 500 1 (1.8) 1 (1.8) 0 (0) 1 (1.8) 1 (1.8) 0 (0) 0 (0) 0 (0) 0 (0)
Percentages shown in parentheses. Bazett’s, Karen, and Fridericia’s are different forms of QT correction for heart rate, calculated by dividing the QT interval by a power of the RR interval;
for Bazett’s, this is 0.5; for the Karen it is 0.4; and for Fridericia’s, it is 0.33.
* Cutoffs used are taken from FDA guidelines.
MYTTON AND OTHERS 448served on the third day of illness is greater than the FDA’s
conservative threshold of concern for cardiotoxicity, it did not
breach the level for high concern. Importantly, the QTc pro-
longation observed is comparable with that observed at this
time with other antimalarials, shown in Table 4, using the
same correction (Bazett’s). This includes drugs with no
known cardiac effects, which suggests that QT prolongation
may have resulted from recovery from malaria and be unre-
lated to drug treatment. The value is less than the prolonga-
tion reported with chloroquine, the most widely used antima-
larial, and substantially less than that associated with halo-
fantrine, which is associated with sudden death.
16 QTc
prolongations > 60 ms were within the bounds of normal daily
variation in the QTc (up to 75–100 ms).
10 The observed in-
creases in the QTc intervals were due to JT prolongation (i.e.,
repolarization) rather than QRS prolongation (depolariza-
tion) in contrast to chloroquine, which produces predomi-
nantly QRS prolongation.
17 Quinidine and halofantrine,
which are associated with a significant risk of arrhythmia,
cause significant JTc prolongation of much greater magnitude
than observed with DP treatment but little QRS prolonga-
tion.
16,19,20
Whether the observed QTc/JTc prolongation is a drug ef-
fect, an effect of malaria, or a response in recovery from a
febrile illness remains uncertain.
7,11,14,15 The relatively ho-
mogenous changes in the QTc for a range of structurally un-
related antimalarials suggest the latter. The PR interval was
significantly prolonged at 52 hours, this would be expected
with a fall in the heart rate and the magnitude of change is not
clinically meaningful
In a population PK evaluation of piperaquine, from the
same study, it was estimated that peak concentrations of pi-
peraquine occurred 8 hours after dosing (K. Stepniewska, un-
published data). It is possible that more profound changes in
QTc may have been missed, although our estimate of QTc
prolongation is similar to 11 ms observed for DP by others.
11
Larger studies in patients of all ages, including healthy vol-
unteers, with concomitant piperaquine drug assay would
strengthen the safety data.
Although some QT prolongation has been observed, the
risk appears to be similar to other antimalarials and consid-
erably less than that observed with drugs with clinically rel-
evant cardiotoxicity. The absence of adverse cardiac events or
significant ECG abnormalities in this series of 56 patients or
the Cambodian series is reassuring. DP is one of the leading
antimalarial candidates available and is likely to be deployed
on a large scale once it has been registered internationally.
The accumulating evidence of high efficacy and safety of this
drug suggests that this process should be expedited.
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